Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Lorlatinib for ALK Fusion Locally Advanced Non-small Cell Lung Cancer
NCT05740943Phase 2Active, not recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Started Mar 2023; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05740943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740943.